Physician profile
Jane Pollner
NPI 1265459812
$8,246.94
in general payments reported to CMS, 2019-2025
27 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $326 · 2021: $1,163 · 2022: $1,553 · 2023: $1,547 · 2024: $1,549 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,320.84 |
| Education | $142.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,071.57 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $1,873.37 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $791.45 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Theratechnologies INC. | $509.80 | 2019-2025 | Trogarzo, Egrifta |
| Abbvie INC. | $417.55 | 2021-2025 | |
| Janssen Biotech, INC. | $385.55 | 2019-2023 | Symtuza |
| Shionogi INC | $303.23 | 2024-2025 | Fetroja |
| Napo Pharmaceuticals INC | $300.17 | 2019-2022 | |
| Melinta Therapeutics, LLC | $235.42 | 2022-2024 | Vabomere, Kimyrsa, Rezzayo |
| Janssen Products, LP | $227.99 | 2020-2021 | |
| Insmed, INC. | $192.60 | 2020-2024 | Arikayce |
| Astellas Pharma US INC | $170.05 | 2021-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $142.49 | 2022-2025 | Xerava, Xacduro, Zevtera |
| Paratek Pharmaceuticals, INC. | $119.14 | 2022-2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $101.18 | 2023-2025 | Vowst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $90.14 | 2022-2023 | Hyqvia |
| Pfizer INC. | $90.03 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $43.24 | 2024-2025 | Rebyota |
| Allergan, INC. | $34.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Mylan Institutional INC. | $20.88 | 2019 | |
| Philips North America LLC | $19.31 | 2019 | |
| Vyera Pharmaceuticals, LLC | $19.06 | 2019 | |
| Dynavax Technologies Corporation | $17.09 | 2022 | |
| Janssen Scientific Affairs, LLC | $17.04 | 2021 | |
| Smith+Nephew, INC. | $13.17 | 2021 | |
| Tactile Systems Technology INC | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Pollner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.